Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00092339Phase 3Completed
Phase 3, randomised, double-blind trial of rofecoxib in postoperative pain (3 arms), sponsored by Merck & Co. Primary endpoint: Overall analgesic effect as measured by total pain relief over 12 hours. Started Aug 2002; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00092339.